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ABSTRACT  
Objective:  To examine the feasibility of a trial allocating different blood pressure 
(BP) intervention levels for treatment in extremely preterm infants.  
Design:  Three-arm open randomised controlled trial performed between February 
2013, and April 2015. 
Setting: Single tertiary level neonatal intensive care unit.  
Patients: Infants born <29weeks gestation were eligible to participate, if parents 
consented and they did not have a major congenital malformation.  
Interventions: Infants were randomised to different levels of mean arterial BP at 
which they received cardiovascular support: Active (<30mmHg), Moderate 
(<Gestational age mmHg) or Permissive (signs of poor perfusion or <19mmHg).  
Once this threshold was breached, all were managed using the same treatment 
guideline.  BP profiles were downloaded continuously; cardiac output and carotid 
blood flow were measured at 1and 3 days, amplitude integrated EEG was recorded 
during the first week.  Cranial ultrasound scans were reviewed blind to study 
allocation. 
Main outcome measure: Inotrope usage and achieved BP. 
Results: Of 134 cases screened, 60 were enrolled, with mean gestation 25.8 weeks 
(SD 1.5) and birth weight 817g (SD 190).  Invasively measured BP on the first day, 
and inotrope usage, were highest in the Active and lowest in the Permissive arms.  
There were no differences in hemodynamic or EEG variables, or in clinical 
complications. Predefined cranial ultrasound findings did not differ significantly; no 
infants in the Active arm had parenchymal brain lesions.   
Conclusion: The BP threshold used to trigger treatment affects the achieved BP and 
inotrope usage, and it was possible to explore these effects using this study design.  
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INTRODUCTION 
 
The management of cardiovascular disturbances in extremely preterm infants differs 
considerably between neonatal units.1-6 Blood pressure (BP) is routinely measured, 
some studies show low BP on the first day is associated with adverse outcomes,7 but 
observational studies have not shown links with neurodevelopmental sequelae.8 9 The 
criteria for supporting low BP has been identified as a research priority.10  
 
With challenges in estimating cardiac output and systemic vascular resistance, BP is 
frequently used as a proxy.11-13 The ‘normal’ range of BP for extremely preterm 
infants remains elusive and whether such ranges ensure optimal organ perfusion 
remains unknown.2 14  
 
Over two decades ago a pragmatic approach was proposed to maintain mean arterial 
BP (MABP in mmHg) above the gestation of the infant in weeks15 and this remains 
widely practiced.4 5 16 Some units practice permissive hypotension whereby BP is not 
supported without clinical or biochemical evidence of poor perfusion. A minority of 
units maintain MABP above 30 mmHg16, with some studies showing cerebral white 
matter changes17 or impaired autoregulation18 with BP below this level.  
 
Observational studies have suggested an association between treatment for 
hypotension and adverse outcomes.19 Anti-hypotensive treatment may simply identify 
cardiovascular instability, but could itself be harmful.  Randomised trials need to 
examine whether low BP in extremely preterm infants should be supported, to assess 
whether inotropic agents are beneficial or harmful, and to determine BP levels at 
which clinicians should intervene.   
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The aim of this study was to compare in extremely preterm infants (≤28 weeks), 
different BP intervention levels at which clinicians should commence circulatory 
support in the neonatal unit (these intervention levels were MABP <30mmHg, MABP 
<gestation, or treating impaired perfusion and/or MABP <19mmHg).   We 
hypothesised that a higher BP intervention level would represent a lower threshold for 
treatment, resulting in higher achieved BP during the first week of life, and more 
inotropic agent usage during the infant’s neonatal unit admission. 
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METHODS 
 
Study design 
This 3-arm parallel pilot single centre randomised clinical trial investigated 
intervention levels for BP support in extremely premature neonates. It was conducted 
in a tertiary medical and surgical neonatal intensive care unit (NICU) with 36 cots and 
over 600 annual admissions.     
 
Participants 
Infants were eligible if born <29 weeks gestation, recruited and randomised within 12 
postnatal hours. The only exclusions were major congenital malformation, lack of 
parental consent, or lack of assent from clinicians. Written information was provided 
to parents when delivery was anticipated, and parents offered assent before delivery. 
Written consent was obtained within 12-hours following delivery. For unexpected 
deliveries or postnatal transfers, this took place after admission. Postnatal consent was 
required by the ethics committee, following a parent consultation in which 67% stated 
a preference for formal postnatal consent before recruitment.   
 
Randomisation and masking 
Randomisation was performed using stratification in individual weeks of gestation, 
with permuted blocks of 3 patients. A random number generator allocated blocks, 
with allocation concealed in sequentially numbered opaque sealed envelopes (by 
STK). Clinicians were unaware of block size, all allocations were concealed and 
administered in correct order with no deviations.  Following recruitment, a different 
team member (SSP) opened the envelope to reveal the BP intervention level.   
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Intervention 
Infants were randomised into one of three arms.   They received BP support if they 
met these criteria: 
i. Active arm: Mean arterial BP (MABP) was supported if it fell below 30 
mmHg for more than 15 consecutive minutes 
ii. Moderate arm: MABP was supported if it fell below the infants gestational 
age in mmHg for more than 15 consecutive minutes 
iii. Permissive arm: Cardiovascular support was given for clinical evidence of 
impaired tissue perfusion assessed by the clinician (poor skin perfusion with 
capillary refill time >3 seconds, urine output <1 ml/kg/hour from weighing of 
urine, worsening base excess (<-8mmol/L) or rising lactate (>2mmol/L) on 
blood gas analysis) and/or if MABP fell below a lower safety net value of 19 
mmHg for more than 15 consecutive minutes.  Infants also qualified for 
cardiovascular support if MABP remained ≥19mmHg with evidence of 
impaired tissue perfusion. 
 
The threshold of 19 mmHg in the Permissive arm was arbitrarily chosen, as the lowest 
value which clinicians accepted, giving separation from the lowest Moderate arm 
value.  
 
Infants received the same BP management across the three arms of the study. The 
therapeutic goal of cardiovascular support was to achieve a MABP (or measure of 
tissue perfusion) which was greater than the threshold at which the infant became 
eligible for the intervention. 
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Circulatory management 
BP management prior to randomisation followed the unit’s established guidelines, the 
same as in the Active arm. Perinatal management included antenatal steroids, a 
modest delay in umbilical cord clamping (30-60sec), with no routine intravascular 
volume before NICU.  
  
A written protocol tailored for each gestation and study arm was at the cotside to 
guide staff, with BP intervention levels.  Apart from this target, the guideline 
(Appendix A) was similar to standard NICU policy.  Key elements included triggers 
for evaluation (BP, tachycardia, impaired perfusion), basic stabilisation, and a 
maximum of 10-20mls/kg intravascular volume.  First-line inotropes were dopamine 
for low BP, and dobutamine for poor perfusion.  If inotropes were escalated, clinical 
re-evaluation was performed, usually involving functional echocardiography to target 
treatment (options included intravascular volume, second inotropes, pressors, 
hydrocortisone, pulmonary vasodilators or PDA treatment). Clinician discretion in 
starting inotropes was allowed, assessing overall clinical status, so starting therapy 
before breaching BP threshold was not a protocol deviation. Clinicians were not 
blinded to the various intervention groups. 
 
All infants had amplitude integrated electroencephalography (aEEG), right common 
carotid artery blood flow (RCCAF) volume, left ventricular output (LVO) and 
superior mesenteric artery (SMA) velocity measurements on days 1 and 3. 
 
Blood pressure monitoring 
Infants with both invasive and non-invasive BP monitoring were included to reflect 
clinical practice, where invasive BP monitoring is not universally instituted. The 
decision to monitor BP invasively was made by the responsible clinician.   
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Invasive BP measurements were obtained from transducers attached to umbilical 
arterial catheters in a high position (thoracic vertebral body level T6-10) calibrated 
daily at the mid-axillary line. Precautions were taken to ensure good quality 
waveforms, displayed using GE Healthcare systems (Carescape Monitor B850) and 
downloaded onto a laptop every 10 seconds for the first week.   
 
Non-invasive BP was performed every 15 minutes if below threshold, otherwise 
hourly for the first 12 hours and 4-hourly thereafter, using the GE oscillometric 
method with appropriate sized cuffs.  
 
Physiological measurements 
Blood flow measurements were performed using Doppler ultrasound and diameter 
measurement with a Phillips iE33 system (Bothwell, USA).  A 4–12 MHz transducer 
was used for LVO using an apical view20 which correlates well with phase contrast 
MRI.21 A 7–15 MHz probe was used to measure RCCAF volume using an established 
method22 shown to have good reproducibility. A 5–8 MHz transducer was used for 
SMA velocity.23 
 
Electroencephalography recording 
aEEG was recorded for 72 hours using a 2–channel BRM3 monitor (BrainZ 
Instruments, Canada). Hydrogel electrodes were placed in the centro-parietal regions 
(C3–P3, C4–P4) bilaterally according to the 10–20 system24. A 2–hour artefact and 
seizure free electroencephalogram trace, recorded before and after RCCAF 
measurement was analysed. Cross-cerebral aEEG was assessed for median, minimum 
and maximum amplitude. The discontinuity of the trace was calculated from the raw 
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electroencephalogram (threshold 20 microvolts) using software25 in MATLAB® (The 
MathWorks Inc., USA).  
 
Classification of cerebral pathology on Cranial ultrasound scan (CrUSS) 
Unit policy was for CrUSS on Days 1,3,7,14,28 and at 36 weeks corrected age, or 
before discharge.  All first week CrUSS, and the CrUSS closest to 36 weeks, were 
reviewed independently by two neonatal consultants (STK & AKS) blind to allocation.  
Periventricular haemorrhage (PVH) was classified on the Papile scale26; later findings 
included porencephalic cyst, periventricular leukomalacia and ventricular dilatation.  
 
Clinical and Physiological Outcomes 
Predefined primary outcomes were MABP during the first week, and the use/duration 
of inotropes.  Predefined secondary clinical outcomes included death or parenchymal 
brain abnormality on cerebral ultrasound, death before discharge home from hospital,  
periventricular leukomalacia, parenchymal or other periventricular haemorrhage, 
necrotising enterocolitis using Bell’s staging criteria and localised intestinal 
perforation, treatment for patent ductus arteriosus, maximum serum creatinine and 
potassium in the first 2 weeks, duration of respiratory support, oxygen dependency or 
respiratory support at 36 weeks post-conceptual age, postnatal steroids including 
hydrocortisone.  
Physiological outcomes were RCCAF, SMA blood flow velocity, LVO and EEG 
measurements, as detailed above. 
 
Statistical analysis 
 
Sample size calculations were performed for 80% power at a 5% significance level, 
with 2-sided tests in a 3-armed study design, without correction for multiple 
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comparisons.  For the primary outcome of inotrope usage, previous data showed rates 
of 15% where permissive hypotension was practiced27 and 68% in our unit using 
active management (unpublished data). Sample size was calculated from a 15% vs 
65% difference in proportions, with continuity correction, requiring 18 patients in 
each group (STATA, version 14, StataCorp 2015).  Inotrope usage was used in these 
calculations as data was not available for duration of inotrope usage nor MABP 
during the first week.  A planned study size of 20 patients in each study arm was used 
to allow for attrition or uneven recruitment. 
 
To reduce multiple pairwise testing, data were examined for effects across three 
treatment arms, using tests for ordered effects (assuming 
Active>Moderate>Permissive).  For normally distributed continuous variables this 
used ANOVA and predefined contrasts, for non-normal data the Jonckheere–Terpstra 
test.  For categorical outcomes Chi-squared test with Linear–by–Linear association 
was used, or Fisher’s exact test for predicted cell numbers<5.   
 
After excluding artefacts, invasive BP during the first 3 days was analysed in a mixed 
effects general linear model, with random effects included in the intercept of the  
model to account for between-baby variation, and gestation modelled as a fixed effect 
by completed week of gestation, and time as a fixed effect by 4–hourly epochs. 
 
As an exploratory pilot trial, tables give statistical significance without correction for 
multiple testing, but also indicate whether p–values remain significant using the 
Benjamini–Hochberg correction28, with a false discovery rate of 10% for each 
analysis (clinical outcomes and physiological outcomes).   
 
This study received approval from the London-Surrey Borders Research Ethics 
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Committee (reference 12/LO/1553), NHS National Research Ethics Service.   
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RESULTS 
Patient characteristics 
The trial ended after planned recruitment of 60 infants between February 2013 and 
April 2015.  This represented 45% of 134 NICU admissions within eligible gestation 
and postnatal age ranges (Figure 1).  In two patients clinicians requested that the 
patient should not be recruited because of a clinical and echocardiographic diagnosis 
of persistent pulmonary hypertension of the newborn (PPHN).  There were no 
differences between those recruited, and those who were not, in mean gestation (25.8 
vs 26.0 weeks), inborn proportion (70% vs 64%) or mortality (15% vs 19%).  
 
No parents gave antenatal assent.  All those recruited were followed up and included 
in the analysis with no protocol deviations.  Clinician discretion in starting inotropes 
was allowed, assessing overall clinical status, so starting therapy before breaching BP 
threshold was not a protocol deviation.  Median randomisation age was 8 hours (range 
1-12).  Randomised groups were comparable (Table 1). 
 
Patient characteristics Active arm 
(n = 19) 
Moderate arm 
(n = 20) 
Permissive arm 
(n = 21) 
p-
value 
  
Gestational age in weeks 25.7 (23.4 – 28.9) 25.8 (23.3 – 28.7) 25.6 (23.7 – 28.7) .91 
Birth weight in grams 760 (580-1000) 810 (470-1180) 790 (540-1470) .42 
Females, n (%) 11 (58%) 8 (40%) 11 (52%) .75 
Antenatal steroids, n (%) 
     No steroids 
     Two doses of steroids 
 
1 (5%) 
16 (84%) 
 
2 (10%) 
14 (70%) 
 
1 (5%) 
15 (71%) 
 
.84 
Mothers who received anti-
hypertensive medication, n 
(%) 
 
4 (21%) 
 
4 (20%) 
 
2 (10%) 
 
.57 
Mothers who received 
magnesium sulphate, n (%) 
No data available, n (%) 
5 (26%) 
 
14 (74%) 
5 (25%) 
 
15 (75%) 
1 (5%) 
 
20 (95%) 
 
.58 
 
Mode of delivery, n (%) 
    Vaginal delivery 
    Caesarean section 
 
15 (79%) 
4 (21%) 
 
17 (85%) 
3 (15%) 
 
20 (95%) 
1 (5%) 
 
.28 
Apgar score 
     1 min 
     5 min 
 
5 (0 – 9) 
8 (1 – 10) 
 
5 (1 – 9) 
7 (4 – 10) 
 
3 (1 – 9) 
7 (3 – 10) 
 
.21 
.96 
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Temperature on admission 
to NICU 
36.9 (33.4 – 37.8) 36.9 (35.5 – 37.5) 36.8 (35.8 – 38.1) .65 
CRIB II scores 13 (8 – 17) 12 (8 – 16) 12 (5 – 15) .10 
Invasive ventilation, n (%) 
  Day 1 
  Day 3 
 
        18 (95%) 
16 (84%) 
 
        18 (90%) 
15 (75%) 
 
        20 (95%) 
11 (52%) 
 
  .84 
.08 
Mean airway pressure, cms 
of H2O 
  Day 1 
  Day 3 
 
 
8 (4 – 11) 
8 (5 – 15) 
 
 
9 (5 – 11) 
8 (6 – 15) 
 
 
7 (5 – 9) 
7 (4 – 10) 
 
 
.05 
.02 
 
Table 1: Perinatal characteristics at the time of recruitment and randomisation. Where not 
specified all figures are median (range).  None of the differences were significant after 
correction for multiple testing.   
 
Blood Pressure and Cardiovascular Support 
Initial analysis of intermittent, staff-recorded BP, including both invasive and non-
invasive measurements, did not show MABP differences between groups. A MABP 
<19 mmHg was found in 4 infants in the Permissive, none in the Moderate and one in 
the Active arm. Non–invasive MABP measurement was on average 11mmHg higher 
than the preceding invasive value; the 95% limits of agreement between staff-recorded 
and continuously downloaded invasive BP was +/- 6mmHg, with no systematic bias.  
Detailed analysis of BP was therefore restricted to 51 infants (85%) with continuous 
invasive BP monitoring between 12-72 hours.   
 
On the first postnatal day, invasive BP was highest in the Active arm, and was most 
stable in this group, with no significant effects in any time epoch during the first 3 
days (Figure 2).  In the Moderate arm, BP was significantly reduced at 12–15 hours of 
age (-3.1mmHg, 95%CI -5.2 to -1.0), and overshot to become significantly elevated at 
32–39 hours of age (+3.5mmHg at 36–39 hrs, 95%CI 1.3 to 5.6).  In the Permissive 
arm, BP was significantly reduced at 8–19 hours of age (-5.2mmHg at 12–15 hrs, 
95%CI -6.3 to -4.1), with a short period of elevation at 24–27 hours (+1.7mmHg, 
95%CI 0.6 to 2.7).  After 72 hours, there were no major differences in BP between the 
groups (Supplementary table 1).    
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Inotropic support was given most frequently, and for longest duration, in the Active 
arm (79% inotropes, mainly dopamine), and was used least in the Permissive arm 
(48%, p=0.05). Although 12/35 (34%) of the patients receiving inotropes had their 
treatment started before randomisation, this did not differ between groups, and after 
randomisation inotropes were started significantly more often in the Active arm.  
Intravascular volume use prior to inotropes was similar in different study arms 
(Active 7/15, Moderate 8/10, Permissive 8/10).  In the Permissive arm, 3 infants had a 
MABP <19 mmHg recorded in the hour that inotropes were started. There were no 
differences in hydrocortisone use, intravascular volume expansion or in PDA 
treatment (Table 2). 
 
 Active arm 
n = 19 
Moderate arm 
n = 20 
Permissive arm 
n = 21 
p-value 
 
P(c) 
Clinical cardiovascular treatment: Intravascular volume expansion 
Pre-randomisation, (ml/kg) 
 
During 72 hours post 
randomisation, (ml/kg) 
 
Total volume expansion given in 
the first week (ml/kg) 
0 (0 – 10) 
 
 
30 (15 – 50) 
 
 
65 (15 – 85)  
0 (0 – 10) 
 
 
15 (0 – 33) 
 
 
40 (0 – 68)  
0 (0 – 8) 
 
 
23 (0 – 49) 
 
 
35 (0 – 89)  
.94J 
 
 
.30J 
 
 
.28J 
 
Clinical cardiovascular treatment: Inotropic agents 
Inotropic support (n) 15 (79%) 10 (50%) 10 (48%) .05  
Inotrope usage by gestation (n) 
 23 – 24 weeks 
 25 – 26 weeks 
 27 – 28 weeks 
 
5/5 (100%) 
8/10 (80%) 
2/4 (50%) 
 
5/6 (83%) 
4/10 (40%) 
1/4 (25%) 
 
5/5 (100%) 
4/11 (36%) 
1/5 (20%) 
- 
 
Age inotropes started (hours) 
Started before randomised (n) 
Started after randomised (n) 
8 (5 – 12) 
2 (11%) 
13 (68%) 
5 (4 – 13) 
6 (30%) 
4 (20%) 
8 (4 – 92) 
4 (19%) 
6 (29%) 
 .82J 
.53 
.01 
 
 
* 
Duration of inotropes (hours) 
All infants 
Infants receiving inotropes 
 
44 (20 – 153) 
56 (31 – 197) 
 
7 (0 – 73) 
68 (37 – 118) 
 
0 (0 – 39) 
39 (34 – 42) 
 
.01J 
.07J 
 
* 
 
Inotropic agents used (n) 
 Dopamine 
 Dobutamine 
 
15 (79%) 
2 (10%) 
 
10 (50%) 
1 (5%) 
 
8 (43%) 
3 (14%) 
 
   .03 
   .77F 
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Maximum dose of dopamine - 
mcg/kg/min 17 (10 – 20) 12 (10 – 16) 11 (10 – 14) .09
A  
Clinical cardiovascular treatment: other cardioactive drugs and monitoring 
Hydrocortisone for hypotension (n) 4 (21%) 3 (15%) 4 (19%) .92F  
Patent ductus arteriosus (n) 
  Medical treatment (COX 
inhibitor) 
  Surgical ligation 
 
7 (37%) 
2 (10%) 
 
9 (45%) 
2 (10%) 
 
8 (38%) 
5 (24%) 
 
    .95 
.48F 
 
Invasive BP monitoring 17 (89%) 18 (90%) 16 (76%) .48F  
Duration of umbilical arterial 
catheterisation – hours 
105  
(68 – 232) 
108  
(55 – 227) 
79  
(45 – 187) .22
J  
Physiological characteristics on day 1 and 3 of life: Circulatory variables 
Cardiac output (left ventricular output, ml/kg/min) 
    Day 1 
    Day 3 
166 (159 – 220) 
 210 (147 – 256) 
160 (125 – 195) 
 220 (164 – 250) 
181 (144 – 202) 
 200 (172 – 251) 
   .58A 
    .67A 
 
Mean arterial (invasive and non-invasive) blood pressure (mmHg) during echocardiography 
    Day 1 
    Day 3 
 36 (33 – 38) 
 36 (33 – 39) 
 32 (29 – 35) 
 33 (29 – 41) 
34 (28 – 37) 
40 (32 – 51) 
   .65A 
   .33A 
 
Mean arterial (invasive) blood pressure (mmHg) during echocardiography 
     Day 1 
     Day 3 
35 (32 – 37) 
34 (32 – 36) 
32 (29 – 35) 
32 (28 – 35) 
31 (27 – 35) 
33 (30 – 39) 
  .01A 
  .56A 
 
Common carotid artery blood flow (ml/kg/min) 
    Day 1 
    Day 3 
12 (10 – 14) 
 15 (12 – 18) 
12 (8 – 14) 
 13 (12 – 15) 
12 (9 – 16) 
 15 (11 – 20) 
 .41A 
   .66A 
 
Superior mesenteric artery blood flow velocity (mean of peak velocity envelope - cm/s) 
    Day 1 
    Day 3 
21 (16 – 29) 
 21 (14 – 27) 
29 (15 – 35) 
 30 (24 – 40) 
21 (17 – 28) 
 26 (22 – 31) 
 .84A 
.04A 
 
Patent ductus arteriosus 
Patent ductus arteriosus (PDA) present (n (%))  
    Day 1 
    Day 3 
18 (95%) 
12 (63%) 
19 (95%) 
13 (68%) 
17 (81%) 
15 (71%) 
 .35F 
    .58  
 
PDA maximum (colour) diameter (mm) 
    Day 1 
    Day 3 
1.6 (1.2 – 1.9) 
1.1 (0 – 1.6) 
1.3 (1 – 1.8) 
1.1 (0 – 1.6) 
1.3 (1.2 – 1.8) 
1.2 (0 – 1.5) 
.13A 
.94A 
 
PDA maximum velocity (m/sec) 
    Day 1 
    Day 3 
1.4 (0.8 – 1.6) 
0.6 (0 – 1.7) 
1.3 (0.9 – 1.6) 
0.9 (0 – 1.4) 
1.2 (0.4 – 1.9) 
0.7 (0 – 1.5) 
.92A 
.70A 
 
PDA flow pattern (n(%)) as per Su et al29 
   Day 1:  Growing pattern 
                Pulsatile pattern 
6 (50%) 
9 (39%) 
3 (25%) 
9 (39%) 
3 (25%) 
5 (22%) 
.39F 
 
 
   Day 3:  Growing pattern 2 (40%) 2 (40%) 1 (20%) .80F  
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                Pulsatile pattern 7 (32%) 7 (32%) 8 (36%) 
Physiological characteristics on day 1 and 3 of life: Electroencephalographic variables 
Maximum aEEG amplitude in μV 
    Day 1 
    Day 3 
12.0 (9.8 – 14.3) 
15.0 (8.3 – 20.6) 
10.0 (7.3 – 14.4) 
  16.0 (10.0 –19.8) 
13.1 (9.6 – 15.5) 
13.0 (12.9 – 18.8) 
.45A 
   .82A 
 
Minimum aEEG amplitude in μV 
    Day 1 
    Day 3 
3.1 (2.8 – 3.9) 
 3.5 (2.4 – 5.1) 
2.5 (2.0 – 3.7) 
 4.0 (2.9 – 5.2) 
3.5 (2.5 – 3.9) 
 4.2 (3.4 – 5.3) 
.63A 
   .87A 
 
Median discontinuity in seconds per one minute epoch 
    Day 1 
    Day 3 
20 (15 – 26) 
9.5 (1.5 – 31.9) 
25 (17 – 37) 
 11 (6 – 23.7) 
17 (9 – 30) 
8.5 (0 – 18.6) 
  .41A 
     .49A 
 
 
Table 2: Cardiovascular treatments, circulatory measurements and electroencephalographic variables. 
Values are number (%) or median (IQR), with statistical tests performed for ordered levels (Chi-squared 
test with linear-by-linear association and Jonckheere-Terpstra test (J)), ANOVA with contrasts (A) or 
Fisher’s exact test (F)). Starting inotropic therapy after randomization, and median duration of inotropic 
therapy for all patients, were the only variables that remained significant after Benjamini-Hochberg 
correction for multiple testing (indicated by * under P(c)).  
 
 
Hemodynamic and electroencephalographic variables 
Detailed echocardiography and aEEG were performed simultaneously on Days 1 and 3 
(median 18 and 77 hours). Cardiac output, ductal shunt, RCCAF, aEEG variables did 
not differ significantly between study arms (Table 2).  
 
Clinical outcomes 
There were no significant differences in clinical outcomes, including mortality, 
duration of care, respiratory or gastrointestinal complications, retinopathy or renal 
variables (Supplementary table 2).  
 
Cranial ultrasound findings 
The review of CrUSS findings reclassified clinical team reports in 17% cases.  There 
was blinded agreement in 92%, and full agreement with minor adjustments after 
discussion.   
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Parenchymal PVH occurred in only 2/60 infants.  A normal CrUSS was found most 
often in the Active arm, and combined rates of Grade 2–4 PVH were highest in the 
Moderate arm (Active 0%, Moderate 30%, Permissive 5%; Fisher’s exact p=0.008). 
The predefined outcome of death or parenchymal brain abnormality did not differ 
between groups (Table 3).   
 
 Active n = 19 
Moderate 
n = 20 
Permissive 
n = 21 
p-value 
 
Normal CrUSS on Day 1 16/18 (89%) 14/19 (74%) 16/18 (89%) .47 
Periventricular Haemorrhage in first week of life 
Normal – No PVH 16 (84%) 12 (60%) 16 (76%) .22 
Subependymal 
Haemorrhage 3 (16%) 2 (10%) 4 (19%) - 
Intraventricular 
haemorrhage (no 
dilatation) 
0  3 (15%) 1 (5%) - 
Intraventricular 
haemorrhage with 
dilatation 
0  1 (5%) 0  - 
Haemorrhagic 
parenchymal infarct 0  2 (10%) 0  - 
Late findings 
Normal 15 (94%) 15 (83%) 14 (88%) .86 
Cystic Periventricular 
Leukomalacia  0 0 0 - 
Porencephalic cyst 0 2 1 - 
Ventricular dilatation 1 1 1 - 
Combined early and late findings 
Death or parenchymal 
brain abnormality 4 (21%) 4 (20%) 3 (14%) .84 
Any abnormality on early 
or late scans 4 (21%) 8 (40%) 6 (29%) .44 
 
Table 3: Cranial ultrasound findings, assessed blinded to study allocation.  There were 
no differences in pre-specified outcomes (Fisher’s exact test; all infants with cranial 
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ultrasound abnormalities had invasive BP monitoring on Day 1 and only two infants 
had non-invasive BP monitoring on Day 3.  
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DISCUSSION 
This is the first prospective randomised trial of BP intervention levels in preterm 
neonates to report its findings, demonstrating feasibility of such a study.  This design 
achieved separation between study arms in inotropic therapy and BP levels.  However, 
differences were less than might have been supposed, with major differences in 
invasively measured BP found mainly in the first 2 days.  Differences in inotrope 
usage mainly occurred at 25–26 weeks gestation; most infants below this received 
inotropes, and most infants at higher gestations did not.  The differences between 
intermittent staff BP recordings and continuous invasive measurements, suggest that 
future studies should concentrate on infants with invasive monitoring, using 
automatically downloaded data.  
 
Differences in BP between groups were not reflected in cardiac output or EEG 
variables measured at fixed time points, but these measurements may have missed the 
period when BP differed most. This pilot study was not powered to detect differences 
in major clinical outcomes, and reassuringly there were no effects on mortality.   
 
There were no statistically significant differences in pre-specified cranial ultrasound 
findings between study arms.  However, it was notable that very few infants in the 
Active arm had significant intracranial pathology, only three had subependymal PVH, 
and none had parenchymal lesions.  The highest rates of periventricular hemorrhage 
were found in the Moderate arm.  Fluctuating pressure passive cerebral blood flow in 
sick preterm infants is associated with PVH30 31, so it is biologically plausible that the 
instability of BP in the Moderate arm, could provide a mechanism for more 
intracranial pathology in this group.   
 
The design of randomising patients to different BP intervention levels, but instituting 
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the same management in all study arms, encouraged parents and clinicians to let 
infants participate in the study, with reasonable recruitment.  Added safety by 
measuring cardiac output may have reassured clinicians.   This contrasts with difficult 
recruitment in a trial using fixed intervention levels, with patients randomised to 
treatment or placebo.32 We did not prevent clinical staff from starting inotropes before 
recruitment or when they considered it clinically indicated, even if the BP criteria had 
not been breached for 15 minutes.  As a significant proportion of infants had inotropes 
started before randomisation, we probably underestimated the differences in inotrope 
use which these policies would have produced if instituted from birth, even if the 
policy subsequently modified inotrope duration and dose.  The reasons for starting 
treatment appear to have been based on a number of factors including BP and 
perfusion markers.  Future studies could explore these reasons further, and may find 
larger differences using cluster randomised trials, or with a waiver of consent, if 
considered acceptable to parents. 
 
As an exploratory pilot, this study had limited power for clinical outcome effects.  By 
analysing cardiovascular and EEG measurements at fixed time-points, we may have 
missed perfusion disturbances occurring at different times in each patient. Future 
studies of physiological variables should expect the greatest differences at 12–36 hours 
of age.  Infants did not have pre-trial entry cranial/cardiac ultrasound scans but the 
numbers of infants with normal CrUSS on day 1 did not differ significantly between 
groups. Given the benefits of delayed cord clamping,33 34 a modest delay in cord 
clamping (30-60 seconds) was the standard of care but the exact time of delay was not 
recorded. Inotropic support pre-randomisation was relatively higher in the Moderate 
arm but not statistically different between the arms. Though the effect of delayed cord 
clamping on inotropic support is well described, this does not account for the trend in 
inotropic support post-randomisation, where infants in the Active arm received the 
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most inotropic support.  Volume expansion was given prior to inotropic support in the 
majority of infants, 23 out of 35 (66%), did not differ between study arms, and was not 
related to delayed cord clamping. This study only examined a single aspect of 
cardiovascular management, BP intervention level.  There are many other issues of 
equal importance, to be studied independently, including detection of altered 
perfusion, optimum therapies for hypotension or impaired perfusion, treatment of the 
ductus arteriosus, and whether treatment should be individualised.   
 
We recommend that future studies should concentrate on infants with invasive BP 
monitoring, with data preferably downloaded for analysis.  RCTs may be clinically 
acceptable if there is a safety–net, using echocardiography or other non-invasive 
methods, to detect severe cardiovascular compromise.  Important outcomes can 
include death or neurodevelopmental impairment, but should also examine 
periventricular haemorrhage, using blinded classification of CrUSS.  It may be worth 
examining approaches which are either more or less active than those in common use.   
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What is already known on this topic:  
• The criterion for supporting low BP in extremely preterm infants remains controversial. 
• A gestation based approach to supporting BP remains the most common method.  
• The relation between low BP and adverse outcomes, and the safety of anti-hypotensive 
treatment remains unknown. 
 
 
What this study adds:  
• It is feasible to carry out a 3-arm RCT investigating BP intervention levels in extremely 
preterm infants.  
• The majority of infants below 25 weeks gestation received inotropes irrespective of the 
arm they were randomised to. 
• The BP threshold used to trigger treatment affects achieved BP and inotrope usage. 
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FIGURES 
 
Figure 1. Participant flow through the study. 
Figure 2:  Mean Arterial BP in each study arm, from continuously downloaded BP 
data, averaged in 1-hour periods.  Statistical analysis was performed on data averaged 
in 4-hour epochs, by mixed effects general linear model, with Benjamini-Hochberg 
correction for multiple comparisons. Periods when there were significant effects of 
time epoch and study arm are indicated by blue/dark bars. (Values are hourly mean 
+/-SD, for patients with invasively measured BP only (n=51; Active=17, 
Moderate=18, Permissive=16).
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